Medicine and Healthcare
Fighting Sudden Cardiac Death in Congenital Heart Disease (CHD)
ATROPOS is aimed at enabling the identification of risk factors.
Scientific name of the study
ATROPOS Register for Cases of Sudden Death in Adolescent and Adult Patients with Congenital Heart Disease.
Sudden death is an event that has always remained a mystery to us. In Greek mythology, Atropos, the oldest of the three goddesses of destiny, is the one responsible for cutting the thread of life, which was spun by her youngest sister Klotho and measured by Lachesis, the third of the Fates. The name “Atropos” translates to something like “the Inevitable”. Fateful and inevitable is what sudden cardiac death has felt like to us up until this very day. It is a relatively rare event overall. However, it can particularly affect adolescents and adults with congenital heart disease (ACHD).
Sudden Cardiac Death Is a Particularly Tragic Incident
Thanks to significant advancements in pediatric cardiology and pediatric heart surgery, the number of adult patients with congenital heart disease has been increasing continuously in the past decades. Numerous achievements in medical care such as, for instance, the detection and treatment of heart rhythm disorders in the field of electrophysiology, facilitate a largely “normal” life. However, at the same time, heart rhythm disorders and cases of sudden heart-related death occur more frequently in certain patients with congenital heart disease.
Sudden cardiac death is perceived as being particularly tragic because of its being unexpected. Patients who are suddenly torn from life and their family were doing well subjectively. The risk of sudden cardiac death can hardly be anticipated since so far, a first-time sudden cardiac death (SDC) has not even been able to be predicted by a mathematical risk assessment. By an implantable cardioverter defibrillator (ICD), which is quite frequently implanted for prevention, adolescents and adults with congenital heart disease, in particular,are exposed to disproportionate side effects. The complication rate is high.
Diagnoses with an Increased Risk of SCD
According to the current state of research, there are three diagnosis groups that are particularly associated with an increased SCD risk. As a recent study investigating patients who had suffered sudden cardiac death found, 19 percent of these patients had transposition of the great arteries (TGA) after atrial switch surgery, 16 percent had tetralogy of Fallot (TOF) after corrective surgery and 13 percent had a so-called left-side outflow tract obstruction (LVOTO). According to that, almost half of the studied cases of sudden death (48 percent) were patients that belonged to one of these three diagnosis groups.
Risk Increases Depending on Patient Age
According to medical literature, the yearly SCD risk is 0.19 percent for TOF patients, 0.49 percent for TGA patients after atrial switch and 0.54 percent for patients with LSOTO. This means that, within five years, one out of 100 patients with TOF will die of sudden cardiac death, while one out of 100 patients with TGA after atrial switch or with LSOTO will suffer such an event within two years. In addition, depending on patient age and other clinical characteristics, the yearly risk increases to up to 0.9 percent, which means roughly one sudden cardiac death per year in TOF patients.
-
Background
Medical literature on the investigation of sudden cardiac death
Koyak Z, Harris L, de Groot JR, et al. Sudden cardiac death in adult congenital heart disease. Circulation 2012;126:1944-54. PMID: 22991410
collapse
Nollert G, Fischlein T, Bouterwek S, et al. Long-term survival in patients with repair of tetralogy of Fallot: 36-year follow-up of 490 survivors of the first year after surgical repair. J Am Coll Cardiol 1997;30:1374-83. PMID: 9350942
Khairy P, Harris L, Landzberg MJ, Viswanathan S, Barlow A, Gatzoulis MA, Fernandes SM, Beauchesne L, Therrien J, Chetaille P, Gordon E, Vonder Muhll I, Cecchin F. Implantable cardioverter-defibrillators in tetralogy of Fallot. Circulation. 2008 Jan 22;117(3):363-70. PMID: 18172030
Register Creates Research Basis for Risk Assessment
One sudden cardiac death is still one too many. However, the available models for risk stratification are only of limited suitability to the identification of at-risk patients for preventative intervention. In single medical institutions, SDC in patients with congenital heart disease occurs too rarely to allow for creating bases for valid research. As a result, there is a lack of science-based evidence for a precise risk assessment.
We would like to change that with a Europe-wide register. The ATROPOS Register includes the anonymized data from all patients in Europe with TGA after atrial switch, TOF or LSOTO, who deceased due to sudden cardiac death or who survived such an event. In doing so, it creates the basis for a systematic and quick identification of the risk factors involved. In a next step, we will compare the clinically relevant data of patients deceased due to sudden cardiac death with medical data of patients with similar clinical patterns of the same age group in case control studies.
AI-Based Prevention
In a third step, we will utilize the possibilities of artificial intelligence. Based on the scientifically identified risk factors, so-called deep learning algorithms will be trained to warn the treating physicians, thus facilitating improved diagnostics and prevention that will then allow for targeted medical intervention. We assume that the development of new practical risk models on a large data basis will facilitate a preventive treatment for avoiding SCD. Sudden cardiac death would then be a preventable fate.
Europe-wide Participation
The project is supervised by the EMAH-Center at the Klinik fuer Kardiologie III (department of cardiology III): Center for Congenital and Acquired Heart Defects (EMAH) at Muenster University Hospital. We are calling on physicians from all over Europe to get involved in the data collection for this register and to include any relevant cases that they know of.
-
Your Contribution to the ATROPOS Register
Patient Inclusion Criteria
Inclusion Criteria:
Age of 14 years or older when SCD occurred (deceased or successfully resuscitated)
Diagnosis Groups:
TGA after atrial switch surgery,
TOF after corrective surgery,
Left-side outflow tract lesions (LSOTO) (aortic valve stenosis with bicuspid or tricuspid aortic valve, coarctation of the aorta).Exclusion Criteria:
Age below 14 years at the time of the event,
collapse
post transplantation,
post assist operation,
hypertrophic obstructive cardiomyopathy.
Follow this link to go to the ATROPOS Register.
The research project is supported by the ESC Working Group Grown-up Congenital Heart Disease EuroGUCH and the European Heart Rhythm Association EHRA.
In charge of the project:
-
Prof. Dr. Dr. med. Gerhard-Paul Diller
Gerhard-Paul Diller is Director of the Clinic for Cardiology III: Congenital Heart Defects (EMAH) and Valve Diseases at Münster University Hospital. He is a Visiting Professor at the Imperial College London. More
Gerhard-Paul Diller studied medicine at the Ludwig-Maximilians University in Munich and he received much of his clinical training in Great Britain, at the Royal Brompton Hospital, London. In his research, the certified ACHD expert focuses on adults with congenital heart disease and pulmonary hypertension. In addition, he holds a Master’s degree (M.Sc.) in Health Economics Policy and Management from the London School of Economics, London, UK. Gerhard-Paul Diller has been Director of the Clinic for Cardiology III: Congenital Heart Defects (EMAH) and Valvular Heart Disease at the University Hospital Münster since July 2024. Gerhard-Paul Diller is an executive board member of both the European Heart Rhythm Association and the ESC-Working-Group Grown Up Congenital Heart Disease. Furthermore, he is the deputy chair of the AG 9 Kongenitale Herzfehler (working group on congenital heart disease) of the German Cardiac Society (DGK). Gerhard-Paul Diller is a member of the Competence Network for Congenital Heart Defects where he is also a member of the Review Board.
Universitätsklinikum Münster
Klinik für Kardiologie III: Angeborene Herzfehler (EMAH) und Klappenerkrankungen
Albert-Schweitzer-Campus 1
48149 Münster -
Prof. Dr. med. Helmut Baumgartner
Helmut Baumgartner is the retired director of the Clinic for Cardiology III: Congenital Heart Defects (EMAH) and Valvular Heart Disease at the University Hospital Münster. More
Helmut Baumgartner studied at the medical faculty of the University of Vienna. After spending time as a visiting researcher at institutes such at the Cedars-Sinai Medical Center, University of California, Los Angeles (USA), he directed the Echocardiography Lab, as well as additional different research programs, at the University of Vienna. He was also a member of the Ethical Review Board of the medical faculty at the University of Vienna until 2007, when he accepted a call to the University of Münster. He was granted with numerous awards for his research activities in the field of heart valve disease in adults with congenital heart disease, which include clinical and experimental research on echocardiography and catheter interventions in congenital and acquired heart valve defects, as well as on myocardial vitality. For many years, Helmut Baumgartner was the president of the Austrian Society of Cardiology. For the German Cardiac Society, he acted as a member of the guideline committee for the treatment of heart valve disease and congenital heart disease in adults. He is a member of the European Society of Cardiology (ESC) and an associated editor of the European Heart Journal. Helmut Baumgartner is both a member and deputy chair of the Competence Network for Congenital Heart Defects Management Board. He also acts as a member of the research network’s Steering Committee.
Universitätsklinikum Münster
Klinik für Kardiologie III: Angeborene Herzfehler (EMAH) und Klappenerkrankungen
Albert-Schweitzer-Campus 1
48149 Münster -
Dr. med. Ulrike Bauer
Ulrike Bauer, born in 1958, is the Scientific Managing Director of the National Register for Congenital Heart Defects and the Competence Network for Congenital Heart Defects. More
Ulrike Bauer studied human medicine at the Humboldt University of Berlin. After finishing her doctorate on echocardiography in congenital heart disease, she was a resident for internal medicine at the county hospital in Chemnitz, after which she transferred to the Institute for Cardiovascular Diagnostics at the Charité Berlin. From there she transferred to the department of pediatric cardiology at the German Heart Center, Berlin (Deutsches Herzzentrum Berlin). Under the guidance of Prof. Dr. Peter E. Lange, Ulrike Bauer started setting up a nationwide register for congenital heart disease. The initiative by Prof. Dr. Peter E. Lange lead to the founding of the association of the National Register for Congenital Heart Defects. It was jointly supported by the board of trustees of Deutsches Herzzentrum Berlin and the cardiac societies, as well as by parent and patient associations. The same year was also the kick-off for creating the Competence Network for Congenital Heart Defects, which could took place thanks to government grants. Ulrike Bauer is a member of the German Society of Paediatric Cardiology (DGK), the European Society of Cardiology (ESC), the German Cardiac Society (DGK) and the Association for European Paediatric and Congenital Cardiology (AEPC).
Kompetenznetz Angeborene Herzfehler e. V.
Network Headquarters
Augustenburger Platz 1
13353 Berlin